1. Academic Validation
  2. Tailoring Chemoimmunostimulant Bioscaffolds for Inhibiting Tumor Growth and Metastasis after Incomplete Microwave Ablation

Tailoring Chemoimmunostimulant Bioscaffolds for Inhibiting Tumor Growth and Metastasis after Incomplete Microwave Ablation

  • ACS Nano. 2021 Dec 28;15(12):20414-20429. doi: 10.1021/acsnano.1c08826.
Yuting Shen 1 Liang Chen 2 Xin Guan 1 Xiaoxia Han 1 Xiaowan Bo 1 Shaoyue Li 1 Liping Sun 1 Yu Chen 1 3 Wenwen Yue 1 Huixiong Xu 1
Affiliations

Affiliations

  • 1 Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital; Ultrasound Research and Education Institute, Clinical Research Center for Interventional Medicine, School of Medicine, Tongji University; Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment; National Clinical Research Center for Interventional Medicine, Shanghai 200072, P. R. China.
  • 2 Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P. R. China.
  • 3 School of Life Sciences, Shanghai University, Shanghai 200444, P. R. China.
Abstract

Microwave ablation has attracted the most attention as a locoregional therapeutic method for solid neoplasms. However, the high incidence of incomplete ablation that could promote the rapid Cancer progression still remains a challenge in clinic. Herein, we found that the high invasiveness of residual tumor following incomplete microwave ablation (iMWA) is mainly due to the myeloid cell-mediated immunosuppression. Accordingly, we develop a biohydrogel scaffold-enabled chemoimmunotherapeutic strategy by targeting myeloid cells with a phosphoinositide 3-kinase γ (PI3Kγ) inhibitor (IPI549) to synergize with immunostimulatory chemotherapy (Oxaliplatin, OX) for post-ablative Cancer therapy. With several tumor mouse models, we reveal that OX&IPI549@Gel-based localized chemoimmunotherapy can substantially suppress the growth of tumor post-iMWA, simultaneously evoke robust systemic Anticancer immunity to inhibit metastatic spread, and offer strong long-term immunological memory functions against tumor rechallenge. Besides, this work proposes a potential opportunity for precision medicine by utilizing a mechanism-based rationale to the adoption of our pre-existing arsenal of Anticancer immunotherapeutic schedule.

Keywords

chemoimmunotherapy; immunotherapy; myeloid suppressor cells; nanomedicine; thermal ablation.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100716
    99.69%, PI3Kγ Inhibitor